Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02321098
Other study ID # RD.03.SPR.29106
Secondary ID 2013-000544-26
Status Completed
Phase Phase 4
First received
Last updated
Start date February 2014
Est. completion date January 2016

Study information

Verified date January 2023
Source Galderma R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to compare efficacy, in terms of antifungal activity of Loceryl Nail Lacquer associated with a Cosmetic Varnish and Loceryl Nail Lacquer alone, in the treatment of mild to moderate toenail Distal Subungual Onychomycosis. The second objective of this study will be photographic follow-up of clinical improvement and cure after the initial treatment period of 12 weeks, for 15 additional months.


Description:

Study center: A total of 50 subjects were to be included in 1 site in Iceland. Methodology: - Group Loceryl Nail Lacquer+ Cosmetic Varnish: - Loceryl Nail Lacquer to be applied once weekly for 12 weeks on all affected toenails, - Cosmetic varnish to be applied once weekly for 12 weeks on all affected toenails and/or all toenails. - Group Loceryl Nail Lacquer alone: - Loceryl Nail Lacquer to be applied once weekly for 12 weeks on all affected toenails. - All eligible subejct with no clinical sign of clinical aggravation of Onychomycosis at week 12, could continue to apply Loceryl Nail Lacquer alone, once a week for 15 additional months (or less in case of complete cure).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with a mild to moderate Distal Subungual Onychomycosis (DSO) on at least 1 great toenail chosen as a Target nail - Subjects must have maximum of 50% of nail distal edge involved - Subjects with positive mycological results (direct microscopy and culture) of the Target nail for dermatophytes or Yeast (including Candida) at Screening Exclusion Criteria: - Subjects with clinically important abnormal physical findings at the Screening/Baseline visit - Subjects with Lichen planus, eczema, psoriasis, or other abnormalities of the nail unit - Subjects with known immunodeficiencies, radiation therapy, immune suppressive drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Loceryl NL + Cosmetic varnish
Loceryl NL + Cosmetic varnish once/week for 12 weeks
Loceryl NL 12 weeks
Loceryl NL once/week for 12 weeks
Loceryl NL 15 months
Loceryl once/week for additional 15 months

Locations

Country Name City State
Iceland Principal Investigator Reykjavik

Sponsors (1)

Lead Sponsor Collaborator
Galderma R&D

Country where clinical trial is conducted

Iceland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of Antifungal Activity of Loceryl Nail Lacquer Measurement of diameter of zones of inhibition (mm) produced by residual drug in toenails Week 12
Secondary Absence of Dermatophytes in Nail Samples Culture Week 12
See also
  Status Clinical Trial Phase
Completed NCT02679911 - Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Phase 4
Withdrawn NCT04337749 - Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Prevention of Pitted Keratolysis Phase 4
Recruiting NCT04336514 - A Longitudinal Quantitative Assessment of the Effectiveness of Metatarsal Pads on Plantar Pressures N/A
Completed NCT04332796 - Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination for Treatment of Pitted Keratolysis Phase 4
Withdrawn NCT04000347 - A Study of Efficacy of Benzoyl Peroxide Regimens in Treatment of Unpleasant Foot Odor Phase 4
Completed NCT04000386 - A Study of Efficacy of Zinc Oxide Nanoparticles Coated Socks in Prevention of Unpleasant Foot Odor N/A
Completed NCT02705664 - Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Phase 4